In the Glasgow area, Trichomonas vaginalis continues to be the principal cause of nongonococcal inflammatory conditions of the female genital tract. The original systemic trichomonicidal drug, metronidazole, represented a great therapeutic advance and continues to give good results a decade after its introduction. However, it is not invariably successful, as was noted in the early days by various authors (Rodin, King, Nicol, and Barrow, 1960; Willcox, 1960; Watt and Jennison, 1962 Although this is clinically acceptable there is now a need for an alternative systemic treatment.
Nitrimidazine, an imidazole derivative, has recently been made available, and an assessment of its efficacy forms the subject of the present communication.
Received for publication October 12, 1970 Material and methods 92 female patients (Table I) suffering from trichomoniasis were given 250 mg. nitrimidazine twice daily for 6 days. Patients in transit, previous defaulters, and pregnant women were excluded from the trial. We also planned to treat as many male consorts as possible with the same course of nitrimidazine regardless of whether they had trichomoniasis or not.
The women were re-examined as soon as possible after their initial treatment and again after the first and second menstrual periods following therapy.
Clinical impressions were ignored and the initial diagnosis and specific proof of cure were based solely on the bacteriological findings.
Other venereal diseases were diagnosed in 79 cases (Table II) .
Investigations
Three methods were used to confirm the diagnosis of trichomoniasis.
( (Table III) . Finally, there were twelve cases in which Trichomonas vaginalis was demonstrated at some stage in the follow-up examinations (Table IV) .
Five of these twelve cases were regarded as primary failures and seven as secondary failures. Primary failure was defined as the persistence of the trichomonad at the first examination immediately after therapy. In secondary failure, the trichomonad reappeared after the patient had been shown to be bacteriologically clear at an earlier examination.
Concomitant prophylactic treatment (with 250 mg. nitrimidazine twice daily for 6 days) was given to 28 (31 per cent.) of the male consorts whose sexual partners all responded to treatment. All our treatment failures occurred in women whose consorts remained untreated. Nitrimidazine can be given in a shorter more simplified course, and we believe that it offers a valuable means of systemic treatment for trichomoniasis.
Discussion
We wish to thank Messrs. Carlo Erba who provided the nitrimidazine used in this trial.
of trichomoniasis. 
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